|
|
|
15.07.26 - 20:06
|
Agenus meldet überzeichnete Privatplatzierung von bis zu 340 Millionen US-Dollar zur Weiterentwicklung der zulassungsrelevanten ROBBIN-Studie mit neoadjuvantem BOT+BAL bei MSS-Kolonkarzinom (Business Wire)
|
|
|
Eine Vorabfinanzierung in Höhe von 85 Millionen US-Dollar sowie bis zu 255 Millionen US-Dollar bei Ausübung der Kaufoptionsscheine sollen ROBBIN1 finanzieren, die zulassungsrelevante Phase-3-Studie von Agenus zur neoadjuvanten Therapie mit Botensilimab und Balstilimab (BOT+BAL) bei mikrosatellitenstabilem (MSS) Kolonkarzinom
Die Transaktion ist so strukturiert, dass Agenus bis zu wichtigen wertsteigernden Meilensteinen finanziert ist, darunter vorläufige Topline-Daten zum pathologischen Ansprechen sowie vorläufige und endgültige Analysen zum ereignisfreien Überleben (EFS). Bei vollständiger Ausübung der Kaufoptionsscheine sollen die Erlöse den Betrieb von Agenus bis Ende 2031 finanzieren
Die ROBBIN-Zielpopulation bei MSS-Kolonkarzinom entspricht in den USA einem adressierbaren jährlichen Umsatzpotenzial von mehr als 7 Milliarden US-Dollar – seit über 20 Jahren wurden für diese Patientengruppe keine neuen Therapien zugelassen2,3
Um die Ressourcen auf das Potenzial der neoadjuvanten Therapie z...
|
|
|
|
|
|
|
|
|
14.07.26 - 04:48
|
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus (RTTNews)
|
|
|
Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full-year revenue guidance, among others....
|
|
|
13.07.26 - 16:48
|
MGM Rises on Takeover Bid; SK Hynix Falls on Memory Pullback | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers:
- MGM Resorts International (MGM) shares are rising on a report regarding a potential takeover bid from Barry Diller.
- SK Hynix (SKHY) shares are lower and other memory stocks are also falling. It is lower over concerns with the sustainability of artificial-intelligence spending. The drop in South Korean trading is likely to cause a hit to the American depositary receipts as well. The debate between the optimists and pessimists will continue, which should create volatility, according to Hendi Susanto, portfolio manager at Gabelli Funds.
- Agenus (AGEN) shares are moving higher on news of a deal that it's selling up to $3540 million worth of securities. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
13.07.26 - 12:06
|
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
|
|
|
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer
Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise
ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3
To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer
Company to host conference call and webcast today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
